APO Research
Talk to an analyst

APO RESEARCH · REPORT

Epidermal Growth Factor Receptor (EGFR) Inhibitor

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Analysis and Forecast 2026-2032

22 December 2025192 pages

Choose your research edition.

Industry ResearchEpidermal Growth Factor Receptor (EGFR) Inhibitor Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Epidermal Growth Factor Receptor (EGFR) Inhibitor market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Epidermal Growth Factor Receptor (EGFR) Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Epidermal Growth Factor Receptor (EGFR) Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Epidermal Growth Factor Receptor (EGFR) Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Epidermal Growth Factor Receptor (EGFR) Inhibitor is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Epidermal Growth Factor Receptor (EGFR) Inhibitor include Novartis AG, Eli Lilly and Co., Amgen Inc., AstraZeneca Plc and F. Hoffmann-La Roche Ltd., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Epidermal Growth Factor Receptor (EGFR) Inhibitor, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Epidermal Growth Factor Receptor (EGFR) Inhibitor, also provides the revenue of main regions and countries. Of the upcoming market potential for Epidermal Growth Factor Receptor (EGFR) Inhibitor, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Epidermal Growth Factor Receptor (EGFR) Inhibitor revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Epidermal Growth Factor Receptor (EGFR) Inhibitor revenue, projected growth trends, production technology, application and end-user industry.

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Company

Novartis AG

Eli Lilly and Co.

Amgen Inc.

AstraZeneca Plc

F. Hoffmann-La Roche Ltd.

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Type

Colorectal Cancer

Lung Cancer

Breast Cancer

Others

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Application

Clinic

Hospital

Research Institutes and Research Institutions

Other

Epidermal Growth Factor Receptor (EGFR) Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Epidermal Growth Factor Receptor (EGFR) Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Epidermal Growth Factor Receptor (EGFR) Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Epidermal Growth Factor Receptor (EGFR) Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Epidermal Growth Factor Receptor (EGFR) Inhibitor in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Epidermal Growth Factor Receptor (EGFR) Inhibitor company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Epidermal Growth Factor Receptor (EGFR) Inhibitor revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Colorectal Cancer Major Player Table 3. Lung Cancer Major Player Table 4. Breast Cancer Major Player Table 5. Others Major Player Table 6. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Clinic Major Player Table 8. Hospital Major Player Table 9. Research Institutes and Research Institutions Major Player Table 10. Other Major Player Table 11. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Trends Table 12. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Drivers Table 13. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Opportunities and Challenges Table 14. Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Restraints Table 15. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Share by Region (2021-2026) Table 18. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Share by Region (2027-2032) Table 20. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Players (2021-2026) Table 22. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Key Players Headquarters & Area Served Table 24. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Players, Product Type & Application Table 25. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Type (2021-2026) Table 32. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Type (2027-2032) Table 33. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Application (2021-2026) Table 37. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Application (2027-2032) Table 38. Novartis AG Company Information Table 39. Novartis AG Business Overview Table 40. Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 42. Novartis AG Recent Development Table 43. Eli Lilly and Co. Company Information Table 44. Eli Lilly and Co. Business Overview Table 45. Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 47. Eli Lilly and Co. Recent Development Table 48. Amgen Inc. Company Information Table 49. Amgen Inc. Business Overview Table 50. Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 52. Amgen Inc. Recent Development Table 53. AstraZeneca Plc Company Information Table 54. AstraZeneca Plc Business Overview Table 55. AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 57. AstraZeneca Plc Recent Development Table 58. F. Hoffmann-La Roche Ltd. Company Information Table 59. F. Hoffmann-La Roche Ltd. Business Overview Table 60. F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio Table 62. F. Hoffmann-La Roche Ltd. Recent Development Table 63. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 64. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 65. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 66. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 67. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 68. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 69. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 70. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 71. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 72. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 73. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 74. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 76. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 77. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 78. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 79. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 80. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 81. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 82. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 83. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 84. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 85. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 86. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Region (US$ Million) & (2021-2026) Table 87. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Region (US$ Million) & (2027-2032) Table 88. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026) & (US$ Million) Table 89. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032) & (US$ Million) Table 90. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026) & (US$ Million) Table 91. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032) & (US$ Million) Table 92. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021-2026) & (US$ Million) Table 94. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (US$ Million) & (2027-2032) Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Epidermal Growth Factor Receptor (EGFR) Inhibitor Image Figure 2. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 4. Colorectal Cancer Image Figure 5. Lung Cancer Image Figure 6. Breast Cancer Image Figure 7. Others Image Figure 8. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size Share 2021 VS 2025 VS 2032 Figure 10. Clinic Image Figure 11. Hospital Image Figure 12. Research Institutes and Research Institutions Image Figure 13. Other Image Figure 14. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size (US$ Million) & (2021-2032) Figure 15. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Type (2021-2032) Figure 22. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Application (2021-2032) Figure 25. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032) Figure 27. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032) Figure 28. North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Country (2021-2032) Figure 29. United States Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032) Figure 34. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032) Figure 35. Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Country (2021-2032) Figure 36. Germany Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032) Figure 46. China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032) Figure 47. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032) Figure 49. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032) Figure 50. Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Region (2021-2032) Figure 51. Japan Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032) Figure 59. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032) Figure 60. SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Country (2021-2032) Figure 61. Brazil Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Colorectal Cancer
  • Lung Cancer
  • Breast Cancer
  • Others
Applications
  • Clinic
  • Hospital
  • Research Institutes and Research Institutions
  • Other
Companies covered
  • Novartis AG
  • Eli Lilly and Co.
  • Amgen Inc.
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Type
  3. 1.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Colorectal Cancer
  5. 1.2.3 Lung Cancer
  6. 1.2.4 Breast Cancer
  7. 1.2.5 Others
  8. 1.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market by Application
  9. 1.3.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Clinic
  11. 1.3.3 Hospital
  12. 1.3.4 Research Institutes and Research Institutions
  13. 1.3.5 Other
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Dynamics
  1. 2.1 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Trends
  2. 2.2 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Drivers
  3. 2.3 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Opportunities and Challenges
  4. 2.4 Epidermal Growth Factor Receptor (EGFR) Inhibitor Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Perspective (2021-2032)
  2. 3.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Growth Trends by Region
  3. 3.2.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region (2021-2026)
  5. 3.2.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Players
  2. 4.1.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Players (2021-2026)
  3. 4.1.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Key Players Headquarters & Area Served
  7. 4.4 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Players, Product Type & Application
  8. 4.5 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Market CR5 and HHI
  11. 4.6.3 2025 Epidermal Growth Factor Receptor (EGFR) Inhibitor Tier 1, Tier 2, and Tier 3
5 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Type
  1. 5.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2032)
  3. 5.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Type (2021-2032)
6 Epidermal Growth Factor Receptor (EGFR) Inhibitor Market Size by Application
  1. 6.1 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2032)
  3. 6.3 Global Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Novartis AG
  2. 7.1.1 Novartis AG Company Information
  3. 7.1.2 Novartis AG Business Overview
  4. 7.1.3 Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Novartis AG Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  6. 7.1.5 Novartis AG Recent Developments
  7. 7.2 Eli Lilly and Co.
  8. 7.2.1 Eli Lilly and Co. Company Information
  9. 7.2.2 Eli Lilly and Co. Business Overview
  10. 7.2.3 Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Eli Lilly and Co. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  12. 7.2.5 Eli Lilly and Co. Recent Developments
  13. 7.3 Amgen Inc.
  14. 7.3.1 Amgen Inc. Company Information
  15. 7.3.2 Amgen Inc. Business Overview
  16. 7.3.3 Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Amgen Inc. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  18. 7.3.5 Amgen Inc. Recent Developments
  19. 7.4 AstraZeneca Plc
  20. 7.4.1 AstraZeneca Plc Company Information
  21. 7.4.2 AstraZeneca Plc Business Overview
  22. 7.4.3 AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca Plc Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  24. 7.4.5 AstraZeneca Plc Recent Developments
  25. 7.5 F. Hoffmann-La Roche Ltd.
  26. 7.5.1 F. Hoffmann-La Roche Ltd. Company Information
  27. 7.5.2 F. Hoffmann-La Roche Ltd. Business Overview
  28. 7.5.3 F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue and Gross Margin (2021-2026)
  29. 7.5.4 F. Hoffmann-La Roche Ltd. Epidermal Growth Factor Receptor (EGFR) Inhibitor Product Portfolio
  30. 7.5.5 F. Hoffmann-La Roche Ltd. Recent Developments
8 North America
  1. 8.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (2021-2032)
  2. 8.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2032)
  3. 8.2.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026)
  4. 8.2.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032)
  5. 8.3 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032)
  6. 8.4 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2032)
  7. 8.4.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026)
  8. 8.4.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032)
  9. 8.5 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032)
  10. 8.6 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country
  11. 8.6.1 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021-2026)
  13. 8.6.3 North America Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (2021-2032)
  2. 9.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2032)
  3. 9.2.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026)
  4. 9.2.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032)
  5. 9.3 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032)
  6. 9.4 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2032)
  7. 9.4.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026)
  8. 9.4.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032)
  9. 9.5 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032)
  10. 9.6 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country
  11. 9.6.1 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021-2026)
  13. 9.6.3 Europe Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (2021-2032)
  2. 10.2 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2032)
  3. 10.2.1 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026)
  4. 10.2.2 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032)
  5. 10.3 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032)
  6. 10.4 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2032)
  7. 10.4.1 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026)
  8. 10.4.2 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032)
  9. 10.5 China Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (2021-2032)
  2. 11.2 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2032)
  3. 11.2.1 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026)
  4. 11.2.2 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032)
  5. 11.3 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032)
  6. 11.4 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2032)
  7. 11.4.1 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026)
  8. 11.4.2 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032)
  9. 11.5 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032)
  10. 11.6 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country
  11. 11.6.1 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021-2026)
  13. 11.6.3 Asia Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue (2021-2032)
  2. 12.2 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Type (2027-2032)
  5. 12.3 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Application (2027-2032)
  9. 12.5 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country
  11. 12.6.1 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Epidermal Growth Factor Receptor (EGFR) Inhibitor Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst